Illumina, Inc.

ILMN

US4523271090

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 16:00:00 2024-09-13 EDT			5-day change	1st Jan Change
129.18 ^USD	+2.32%		+3.85%	-7.22%

09-13	RBC Raises Price Target on Illumina to $252 From $242, Keeps Outperform Rating	MT
09-06	European Commission Withdraws Previous Decisions on Illumina-Grail Merger After Court Ruling	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Illumina, Inc.

RBC Raises Price Target on Illumina to $252 From $242, Keeps Outperform Rating	09-13	MT
European Commission Withdraws Previous Decisions on Illumina-Grail Merger After Court Ruling	09-06	MT
European Commission Pulls Certain Decisions in Illumina-Grail Merger Review After Court Ruling	09-06	MT
Illumina Files Mixed Securities Shelf	09-04	MT
Illumina Wins Legal Battle as EU Top Court Annuls Commission's Review of Grail Deal	09-03	MT
Illumina Wins Jurisdictional Appeal in Europe Over GRAIL Acquisition	09-03	MT
Argus Upgrades Illumina to Buy From Hold	08-28	MT
Illumina's TruSight Oncology Biomarker Test Gets FDA Approval	08-27	MT
Illumina, Inc. Announces Food and Drug Administration Approval for Its Cancer Biomarker Test with Two Companion Diagnostics to Rapidly Match Patients to Targeted Therapies	08-27	CI
Will Jerome swap suit for hiking boots?	08-20
Analyst recommendations: JPMorgan, AMD, Chewy, Estee Lauder, Illumina...	08-20
Daiwa Securities Upgrades Illumina to Buy From Neutral, Price Target is $154	08-16	MT
Illumina's Lack of 2025 Guide Left Some Investors Disappointed, RBC Says	08-14	MT
Barclays Upgrades Illumina to Equalweight From Underweight, Price Target is $125	08-14	MT
TD Cowen Upgrades Illumina to Buy From Hold	08-14	MT
Illumina Unveils 3-Year Growth Plan -- Shares Fall	08-13	MT
Illumina, CRISPR-pioneer Broad Institute to work on new gene sequencing kits	08-13	RE
Illumina, Inc. and the Broad Institute of MIT and Harvard Announce New Research Partnership to Advance Single-Cell Sequencing	08-13	CI
Transcript : Illumina, Inc. - Special Call	08-13
UBS Adjusts Illumina Price Target to $133 From $131, Maintains Neutral Rating	08-07	MT
Illumina expects full-year sales from core segment to decline on biotech funding crunch	08-06	RE
Transcript : Illumina, Inc., Q2 2024 Earnings Call, Aug 06, 2024	08-06
Earnings Flash (ILMN) ILLUMINA Reports Q2 Revenue $1.11B, vs. Street Est of $1.09B	08-06	MT
Earnings Flash (ILMN) ILLUMINA Posts Q2 EPS $1.09, vs. Street Est of $0.90	08-06	MT
Illumina, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024	08-06	CI

Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows: - product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.; - sales of services (15.9%). Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).

Employees

10,615

Sector

Advanced Medical Equipment & Technology

Calendar

2024-10-30 - Q3 2024 Earnings Release (Projected)

More about the company